Business Context and Reporting Period
Pulse Biosciences, Inc. filed this Form 8-K on February 21, 2017, reporting events that occurred on February 16, 2017. The filing addresses amendments to the compensatory arrangements for the Company's named executive officers, effective retroactively to January 1, 2017.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation adjustments.
Material Changes
The Compensation Committee and Board of Directors approved increases to annual base salaries and adjustments to annual incentive bonus targets for the following executives:
- Darrin R. Uecker (CEO): Base salary set at $330,000 with a target incentive of 35% of base salary.
- Brian B. Dow (SVP and CFO): Base salary set at $260,000 with a target incentive of 25% of base salary.
Bonus amounts are contingent upon the achievement of annually designated Company performance objectives, determined solely by the Compensation Committee.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, market outlook, or discussion of risks and contingencies beyond the standard discretion of the Compensation Committee regarding performance objectives.
Investor Verification Points
- Verify the specific performance objectives tied to the new incentive bonus targets.
- Confirm the total annual compensation cost impact of these salary and bonus adjustments.
- Review the Company's most recent 10-K or 10-Q for context on cash flow and liquidity to assess the affordability of these increased compensation costs.